Ten-Year Outcomes after Purified CD34+ Cells Transplantation in Patients with Angiitis-induced Critical Limb Ischemia
Abstract Background Angiitis-induced critical limb ischemia (AICLI), which is defined as critical limb ischemia (CLI) caused by thromboangiitis obliterans (TAO) or other arteritis-related autoimmunological diseases. In the current study, we aimed to report the 10-year outcomes of AICLI patients who underwent purified CD34+ cells (PCCs) transplantation. Methods AICLI patients who underwent PCCs transplantation at our center from May 2009 to September 2011 were retrospectively enrolled. The main outcome was major amputation-free survival (MAFS); other outcomes included Rutherford classification, pain-free walking time (PFWT), Wong-Baker Faces Pain Rating Scale (WBFPS), recurrence, new lesions, quality of life (QoL) and patients’ posttransplantation work conditions. Results Twenty-four patients were enrolled with a mean age of 41.5 ± 7.8 years. Three underwent major amputation during the follow-up, and the 10-year MAFS was 87.5%. Eight were observed to have recurrence, and 2 had new lesions; the 10-year recurrence-free rate was 66.1%. All patients were unable to work at admission, 17 (70.8%) patients were reemployed after transplantation. Conclusion The current study further demonstrated satisfactory long-term efficacy of PCCs transplantation, with a 10-year MAFS of 87.5%. However, the 10-year recurrence-free rate of 66.1% suggested that strict and regular long-term follow-up is necessary..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 02. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Hao [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3682001/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA041756398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA041756398 | ||
| 003 | DE-627 | ||
| 005 | 20240405131227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3682001/v1 |2 doi | |
| 035 | |a (DE-627)XRA041756398 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3682001/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Hao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ten-Year Outcomes after Purified CD34+ Cells Transplantation in Patients with Angiitis-induced Critical Limb Ischemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Angiitis-induced critical limb ischemia (AICLI), which is defined as critical limb ischemia (CLI) caused by thromboangiitis obliterans (TAO) or other arteritis-related autoimmunological diseases. In the current study, we aimed to report the 10-year outcomes of AICLI patients who underwent purified CD34+ cells (PCCs) transplantation. Methods AICLI patients who underwent PCCs transplantation at our center from May 2009 to September 2011 were retrospectively enrolled. The main outcome was major amputation-free survival (MAFS); other outcomes included Rutherford classification, pain-free walking time (PFWT), Wong-Baker Faces Pain Rating Scale (WBFPS), recurrence, new lesions, quality of life (QoL) and patients’ posttransplantation work conditions. Results Twenty-four patients were enrolled with a mean age of 41.5 ± 7.8 years. Three underwent major amputation during the follow-up, and the 10-year MAFS was 87.5%. Eight were observed to have recurrence, and 2 had new lesions; the 10-year recurrence-free rate was 66.1%. All patients were unable to work at admission, 17 (70.8%) patients were reemployed after transplantation. Conclusion The current study further demonstrated satisfactory long-term efficacy of PCCs transplantation, with a 10-year MAFS of 87.5%. However, the 10-year recurrence-free rate of 66.1% suggested that strict and regular long-term follow-up is necessary. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Jiang, Xiaolang |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Lingwei |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Shiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Weiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Tianyue |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Zhihui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 02. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3682001/v1 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 04 | ||